PAPaul D. Andrews

Paul D. Andrews

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Paul D. Andrews has a total of 124 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Public–Private Partnerships to Advance Phenotypic Drug Discovery

    by Neil Carragher, Paul D. Andrews, David Carter, Trevor Howe, Denise Barrault, Daniel Ebner

    In this chapter, we discuss the rise and rationale for public–private partnerships (PPP) in phenotypic drug discovery (PDD) from both the academic and industrial perspectives. We then give a review of the three most common “precompetitive” PPP in PDD formats, namely collaborative, co-localized and industry-supported, before finally providing an outlook/conclusion, highlighting the factors we feel contribute to successful PDD partnerships, and the directions we feel these partnerships could take to improve outcomes for both partners.


  • Open Access

    A phenotypic screening platform utilising human spermatozoa identifies compounds with contraceptive activity

    by Franz S Gruber, Zoe C Johnston, Christopher Lr Barratt, Paul D Andrews

    There is an urgent need to develop new methods for male contraception, however a major barrier to drug discovery has been the lack of validated targets and the absence of an effective high-throughput phenotypic screening system. To address this deficit, we developed a fully-automated robotic screening platform that provided quantitative evaluation of compound activity against two key attributes of human sperm function: motility and acrosome reaction. In order to accelerate contraceptive development, we screened the comprehensive collection of 12,000 molecules that make up the ReFRAME repurposing library, comprising nearly all the small molecules that have been approved or have undergone clinical development, or have significant preclinical profiling. We identified several compounds that potently inhibit motility representing either novel drug candidates or routes to target identification. This platform will now allow for major drug discovery programmes that address the critical gap in the contraceptive portfolio as well as uncover novel human sperm biology.


  • Open Access

    A phenotypic screening platform utilising human spermatozoa identifies new compounds with contraceptive activity

    by Franz Gruber, Christopher L.R. Barratt, Paul D. Andrews

    There is an urgent need to develop new methods for male contraception, however a major barrier to drug discovery has been the lack of validated targets and the absence of an effective high-throughput phenotypic screening system. To address this deficit, we developed a fully-automated robotic screening platform that provided quantitative evaluation of compound activity against two key attributes of human sperm function: motility and acrosome reaction. In order to accelerate contraceptive development, we screened the comprehensive collection of 12,000 molecules that make up the ReFRAME repurposing library, comprising nearly all the small molecules that have been approved or have undergone clinical development, or have significant preclinical profiling. We identified several compounds that potently inhibit motility representing either novel drug candidates or routes to target identification. This platform will now allow for major drug discovery programmes that address the critical gap in the contraceptive portfolio as well as uncover novel human sperm biology.

  • Discovering Small Molecules to Control Stem Cell Fate

    by Paul D Andrews

    Pluripotent stem cells promise to revolutionize drug discovery and offer new modes of therapy. The ease with which they can be grown in bulk and their differentiation controlled in vitro is of importance for their widespread adoption by industry and their clinical efficacy. Small molecules have already had a positive impact on several areas of stem cell biology, from maintenance of pluripotency, the promotion of single cell survival and steering differentiation to involvement in reprogramming somatic cells. High-throughput technology has played an important role in identifying novel compounds, however to date there are few published examples of medicinal chemistry input in this area. This review discusses the potential of pluripotent stem cells, the successful uses of small molecules and future prospects.


  • High-content screening of feeder-free human embryonic stem cells to identify pro-survival small molecules

    by Paul D. Andrews, Melissa Becroft, Anders Aspegren, Jane Gilmour, Martyn J. James, Scott McRae, Robert Kime, Robert W. Allcock, Achamma Abraham, Zhong Jiang, et al.

    The propensity of human embryonic stem cells to die upon enzymatic disaggregation or low-density plating is an obstacle to their isolation and routine use in drug discovery and basic research. Equally, the very low rate of establishment of implanted cells hinders cell therapy. In the present study we have developed a high-content assay for human embryonic stem cell survival and used this to screen a range of libraries of ‘lead-like’ small molecules and known bioactives. From this we identified 18 confirmed hits with four structural classes being represented by multiple compounds: a series of 5-(acyl/alkyl-amino)indazoles, compounds with a 4-(acylamino)pyridine core, simple N6,N6-dialkyladenines and compounds with a 5-(acylamino)indolinone core. In vitro kinase profiling indicated that the ROCK (Rho-associated kinase)/PRK2 (protein kinase C-related kinase 2) protein kinases are of pivotal importance for cell survival and identified previously unreported compound classes that inhibited this important biological activity. An evaluation using an extensive panel of protein kinases showed that six of our hit compounds exhibited better selectivity for ROCK inhibition than the routinely used commercially available ROCK inhibitor Y-27632. In this screen we also identified the K+-ATP channel opener pinacidil and show that it probably promotes cell survival, by ‘off-target’ inhibition of ROCK/PRK2. We have therefore identified novel pro-survival compounds of greater specificity, equivalent potency and reduced toxicity relative to the routinely employed ROCK inhibitor Y-27632.


  • Open Access

    In Vivo Imaging of Mammalian Cells: Image Acquisition and Analysis: Figure 1.

    by Jason R. Swedlow, Paul D. Andrews, Melpomeni Platani

    Live cell imaging provides a powerful technique for the analysis of molecular dynamics within cells. Advances in imaging technology and probe design have established this approach as an important tool in modern biology. It is now possible to obtain commercial turnkey systems for digital imaging using a number of different imaging modalities. Nevertheless, it still requires considerable technical care and expertise to conduct a successful experiment. To perform a successful imaging experiment, it is important to maximize the signal-to-noise ratio (S:N) while minimizing damage to the cells. In this article, we focus on the use of fluorescence microscopy in live cell imaging, although most of the points discussed are relevant to any type of imaging. We describe many of the methods and considerations that are required for performing a successful imaging experiment in living cells. However, we do not provide a single recipe for success: The approach is much too empirical and depends on careful observation of the particular cells under investigation.


  • Open Access

    In Vivo Imaging of Mammalian Cells: Cell Engineering and Viability

    by Jason R. Swedlow, Paul D. Andrews, Melpomeni Platani

    INTRODUCTION: There are a number of instances in which the use of live cell imaging has provided critical insight into cellular and tissue function. It has therefore become a requisite analytical tool for use in cell biology, neurobiology, and developmental biology, as well as a routine method practiced in many biomedical research laboratories. The technical requirements for performing live cell imaging include a capacity to engineer appropriate cells for the imaging experiment and access to a digital image acquisition system. The availability of fluorescent protein (FP) technology allows the molecular specificity of fluorescent markers to be used in a genetically encoded manner. In this article, we describe techniques for the generation and maintenance of fluorescently labeled cells and their use in live cell imaging experiments.


  • 17-P003 Discovery of small molecules to control human embryonic stem cell fate

    by Paul D. Andrews, Martyn James, Christine Tosh, Melissa Becroft, Anders Aspergen, Scott MacRae, Nicole Kane, Jane Gilmour, Helena Noren, John McAbney, et al.

  • Phosphorylation by Aurora-B Negatively Regulates Survivin Function During Mitosis

    by Sally P. Wheatley, Rachel M. Barrett, Paul D. Andrews, Rene H. Medema, Simon J. Morley, Jason R. Swedlow, Susanne M.A. Lens

    Survivin operates in a complex with aurora B kinase and is phosphorylated by it on threonine 117 in vitro. Here we ask whether phosphorylation of survivin by aurora B kinase regulates its function during mitosis in vivo. Using a phospho-specific antibody we first establish that survivin is phosphorylated at T117 during mitosis and is present at the midbody during cytokinesis. Next we use two independent RNAi complementation approaches to investigate threonine 117 mutants in survivin depleted cells. Our data suggest that while non-phosphorylatable survivin, survivinT117A, can substitute for the wild type protein, a phosphomimic, survivinT117E cannot restore viability, nor can it complement chromosome congression and spindle checkpoint defects that arise due to depletion of endogenous survivin. Fluorescence imaging and fluorescence recovery after photobleaching analysis suggest that the phosphomimic has reduced affinity for centromeres compared with the non-phosphorylatable form. We conclude that survivin i...


  • Aurora kinases: shining lights on the therapeutic horizon?

    by Paul D Andrews

    The Aurora kinases have been implicated in tumorigenesis and are important regulators of diverse cell cycle events, ranging from the entry into mitosis, centrosome function, mitotic spindle formation, chromosome biorientation and segregation, and cytokinesis. The recent identification of novel binding partners and key downstream effectors, together with new small-molecule inhibitors that display efficacy against tumours, heralds an upsurge of interest in these critical kinases. This review details new developments in the field and analyses the potential of Aurora kinases as anticancer targets.